Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients

Fondation Ophtalmologique Adolphe de Rothschild24 enrolled

Overview

Keratopathy of patients with aniridia leads to epithelial scarring disorders and a progressive clouding of the cornea linked to this abnormal healing (fibrosis). Treatment with autologous serum is usually undertaken to promote epithelial healing. However, autologous serum does not prevent the formation of fibrosis, whereas growth factor-rich plasma appears to be associated with a reduction in the in vitro expression of fibrosis markers. This study seeks to compare the in vitro healing and anti-fibrotic properties of autologous serum and growth factor rich plasma from aniridia patients and healthy controls.

Blood collection from aniridia patients and healthy controls, half of which will be used to make autologous serum and the other half to make growth factor rich plasma, used for in vitro studies. A conjunctival impression will also be taken at the inclusion of the patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Aniridia

Interventions

Peripheral venous blood samplePROCEDURE

2.5% of body weight

Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: For patients with aniridia: * With aniridia * Patient weighing more than 43 kg * If the patient is being treated with autologous serum, a delay of 8 weeks after the last blood collection * If a blood donation has been made, a delay of 8 weeks must be respected after the last donation For controls: * Non-aniridia (no clinical signs) * Weighing more than 43 kg * Matched to a case for sex and age +/-10 years * No known diabetes * If a blood donation has been made, a delay of 8 weeks must be respected after the latter Exclusion Criteria: * Insufficient sample volume * No conjunctival print * HBV, HCV, HIV serology positive * Aniridia not genetically confirmed for cases For each patient excluded, a new patient will be included in order to maintain the number of patients required for data analysis.

Outcomes

Primary Outcomes

In vitro comparison of the corneal cell healing properties of autologous serum and plasma enriched with growth factors from blood of aniridia patients

The corneal cell healing properties are evaluated by the time to reach confluence (number of hours) of epithelial cells, using a standardized wound healing assay (Incucyte, Essenbioscience). The corneal cell healing properties will be comparated between autologous serum, and plasma enriched with growth factors from blood of aniridia patients

Time frame: Sampling done at baseline